Clinical & Translational Oncology最新文献

筛选
英文 中文
Prognostic utility of the CALLY index in metastatic melanoma: building a nomogram for Patients on Anti-PD-1 therapy.
IF 2.8 3区 医学
Clinical & Translational Oncology Pub Date : 2025-03-16 DOI: 10.1007/s12094-025-03888-z
Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, Fatma Pinar Açar, Damla Gunenc, Burçak Karaca
{"title":"Prognostic utility of the CALLY index in metastatic melanoma: building a nomogram for Patients on Anti-PD-1 therapy.","authors":"Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, Fatma Pinar Açar, Damla Gunenc, Burçak Karaca","doi":"10.1007/s12094-025-03888-z","DOIUrl":"https://doi.org/10.1007/s12094-025-03888-z","url":null,"abstract":"<p><strong>Background: </strong>Despite the success of immune checkpoint inhibitors (ICIs) in metastatic melanoma, many patients fail to derive meaningful benefit, underscoring the urgent need for accessible prognostic biomarkers. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index, an immunonutritional index, has shown prognostic value in various cancers. Previous studies indicate that systemic inflammation and nutritional status influence ICI efficacy, suggesting the potential relevance of the CALLY index in metastatic melanoma. This study evaluates the CALLY index's role in metastatic melanoma patients treated with anti-PD-1 therapy.</p><p><strong>Methods: </strong>This retrospective study analysed 92 patients with metastatic melanoma who were treated with anti-PD-1 monotherapy at Ege University's Faculty of Medicine between 2015 and 2023. The CALLY index was calculated using the pre-treatment CRP, albumin and lymphocyte levels. Kaplan-Meier analysis was used to estimate survival outcomes, and univariate and multivariate Cox regression models were employed to identify independent prognostic factors. A predictive nomogram incorporating the CALLY index and other significant variables was then developed.</p><p><strong>Results: </strong>The optimal CALLY index cutoff was determined to be 2. Patients with a low CALLY index (≤ 2) had worse median overall survival (OS) and progression-free survival (PFS) when compared with those who had a high CALLY index (> 2) (median OS: 9.6 vs 31.3 months, p < 0.001; median PFS: 3.8 vs 10.6 months, p = 0.001). Multivariate analysis identified the CALLY index, lactate dehydrogenase above the upper limit of normal, Eastern Cooperative Oncology Group score ≥ 2, M1c/M1d staging and acral/mucosal melanoma subtypes to be independent predictors of OS. A nomogram was then constructed based on these factors, yielding a concordance index of 0.705 (95% confidence interval: 0.634-0.776). This model stratified patients into low-, intermediate- and high-risk groups, with the high-risk group showing significantly worse OS than the intermediate- and the low-risk groups (p < 0.001).</p><p><strong>Conclusion: </strong>The CALLY index is a cost-effective and independent prognostic biomarker that can aid in risk stratification and guide treatment decisions in patients with metastatic melanoma receiving anti-PD-1 therapy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acknowledgement to reviewers 2024.
IF 2.8 3区 医学
Clinical & Translational Oncology Pub Date : 2025-03-15 DOI: 10.1007/s12094-025-03880-7
{"title":"Acknowledgement to reviewers 2024.","authors":"","doi":"10.1007/s12094-025-03880-7","DOIUrl":"https://doi.org/10.1007/s12094-025-03880-7","url":null,"abstract":"","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HER2-targeted therapy in colorectal cancer: a comprehensive review.
IF 2.8 3区 医学
Clinical & Translational Oncology Pub Date : 2025-03-14 DOI: 10.1007/s12094-025-03887-0
Yeliz Benli, Helin Arıkan, Özge Akbulut-Çalışkan
{"title":"HER2-targeted therapy in colorectal cancer: a comprehensive review.","authors":"Yeliz Benli, Helin Arıkan, Özge Akbulut-Çalışkan","doi":"10.1007/s12094-025-03887-0","DOIUrl":"https://doi.org/10.1007/s12094-025-03887-0","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide. Despite treatment advancements in the last decades, CRC remains heterogeneous with significant clinical and genetic diversity. Human epidermal growth factor receptor 2 (HER2) proto-oncogene plays a critical role, as its amplification or overexpression leading to abnormal cell proliferation and tumorigenesis. HER2 overexpression or amplification is identified in 2-4% of metastatic CRCs (mCRC) patients, representing a potential therapeutic target. It is also associated with resistance against epidermal growth factor receptor (EGFR)-targeted therapies like cetuximab and panitumumab, for treatment of RAS wild-type mCRC. Although HER2-positive mCRC is rare, assessing HER2 levels is important. Furthermore, anti-HER2 therapies exhibited non-toxic profile and high efficacy in chemorefractory cases. This review delves into modern management of anti-HER2 therapies in CRC with a particular focus on recent advances and current knowledge about the prognostic and predictive value of HER2.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of telomeres expression in melanoma and cutaneous squamous cell carcinoma: correlation with clinical parameters.
IF 2.8 3区 医学
Clinical & Translational Oncology Pub Date : 2025-03-13 DOI: 10.1007/s12094-025-03876-3
Tuqa Nasser Alsurhi, Asem Shalaby, Shadia Al-Sinawi, Mohamed Mabruk
{"title":"Assessment of telomeres expression in melanoma and cutaneous squamous cell carcinoma: correlation with clinical parameters.","authors":"Tuqa Nasser Alsurhi, Asem Shalaby, Shadia Al-Sinawi, Mohamed Mabruk","doi":"10.1007/s12094-025-03876-3","DOIUrl":"https://doi.org/10.1007/s12094-025-03876-3","url":null,"abstract":"<p><strong>Background and purpose: </strong>The expression of the hTERT component of the human telomerase is elevated in different types of malignancies, including skin cancer. Early diagnosis of malignant melanoma is necessary to improve the prognosis of the disease. Although there are many diagnostic biomarkers for malignant melanoma, none is accurate, specific, and sensitive. The aim of the present study is to evaluate the expression rate and patterns of the hTERT component of human telomerase in melanoma and to compare this with squamous cell carcinoma as a common non melanoma skin cancer to investigate the potential of using telomerase as a molecular biomarker for the early diagnosis of this tumor. Additionally, the study compared the telomerase expression in these two tumor types with varying clinicopathological parameters.</p><p><strong>Methods: </strong>In this retrospective observational study, a total of 348 formalin-fixed paraffin-embedded tissue microarrays samples consisting of cutaneous melanoma (n = 189), squamous cell carcinoma (n = 115), and normal human skin samples (n = 44) were analyzed by immunohistochemistry for the expression of the hTERT component of human telomerase.</p><p><strong>Results: </strong>Out of 189 melanoma cases, 97 (51.3%) showed positive telomerase expression in contrast to detection of telomerase expression only in 3 out of 115 (2.6%) squamous cell carcinoma tissue samples. The telomerase was expressed only in 5 out of 44 normal human skins.</p><p><strong>Conclusion: </strong>Our data indicate that telomerase expression is significantly more pronounced in melanoma compared to squamous cell carcinoma. These findings may support the potential utilization of telomerase as a biomarker for early diagnosis and monitoring of melanoma which can lead to timely treatment and enhances a better outcome.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
IF 2.8 3区 医学
Clinical & Translational Oncology Pub Date : 2025-03-12 DOI: 10.1007/s12094-025-03865-6
Maria Alsina Maqueda, Ana Teijo Quintáns, Miriam Cuatrecasas, Maria Jesús Fernández Aceñero, Ana Fernández Montes, Carlos Gómez Martín, Paula Jiménez Fonseca, Carolina Martínez Ciarpaglini, Fernando Rivera Herrero, Mar Iglesias Coma
{"title":"Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).","authors":"Maria Alsina Maqueda, Ana Teijo Quintáns, Miriam Cuatrecasas, Maria Jesús Fernández Aceñero, Ana Fernández Montes, Carlos Gómez Martín, Paula Jiménez Fonseca, Carolina Martínez Ciarpaglini, Fernando Rivera Herrero, Mar Iglesias Coma","doi":"10.1007/s12094-025-03865-6","DOIUrl":"https://doi.org/10.1007/s12094-025-03865-6","url":null,"abstract":"<p><p>Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA. Four key biomarkers are essential for targeted therapy: HER2 overexpression/amplification, deficient mismatch repair/microsatellite instability (dMMR/MSI), PD-L1, and Claudin18.2 expression. Immunohistochemistry is the recommended method for these biomarkers evaluation. In addition, the assessment of biomarkers like FGFR2b is likely to become routine in the near future. Experts from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have formed a consensus to optimize biomarker detection and usage in clinical practice. Their recommendations aim to improve personalized treatment strategies for GEA and ESCC patients, integrating new diagnostic insights into routine care.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frequency and predictors of caregiver burden among patients with cancer receiving palliative cancer treatment.
IF 2.8 3区 医学
Clinical & Translational Oncology Pub Date : 2025-03-10 DOI: 10.1007/s12094-025-03885-2
Juan Luis Torres-Tenor, Elsa Bernal-Hertfelder, Ana Pertejo-Fernández, Jorge Luis Ramón-Patiño, Andrés Redondo, Alberto Alonso-Babarro, Eduardo Bruera
{"title":"Frequency and predictors of caregiver burden among patients with cancer receiving palliative cancer treatment.","authors":"Juan Luis Torres-Tenor, Elsa Bernal-Hertfelder, Ana Pertejo-Fernández, Jorge Luis Ramón-Patiño, Andrés Redondo, Alberto Alonso-Babarro, Eduardo Bruera","doi":"10.1007/s12094-025-03885-2","DOIUrl":"https://doi.org/10.1007/s12094-025-03885-2","url":null,"abstract":"<p><strong>Purpose: </strong>Assess the frequency of caregiver burden among patients with advanced cancer receiving palliative anticancer treatment. Compare characteristics of those who show caregiver burden versus those who do not.</p><p><strong>Methods/patients: </strong>This is a cross-sectional study in two university hospital oncology departments. Caregivers completed the Reduced Zarit Burden Interview and Emotional Distress Thermometer. Data were analyzed to identify factors associated with caregiver burden.</p><p><strong>Results: </strong>79 informal primary caregivers participated, mostly women (65%, N = 51), middle-aged (median 57, SD = 9), employed (54%), and spouses (58%, N = 46). Most had medium economic status (70%, N = 55), no other dependents (51%, N = 40), support from other caregivers (56%, N = 44), and good self-rated health (82%, N = 65). Caregiver burden affected 61% (N = 48), more often women (p = 0.049), those with high stress (p = 0.001), and when more people were involved in patient care (p = 0.048).</p><p><strong>Conclusions: </strong>Caregiver burden is common in informal primary caregivers of patients with advanced cancer receiving palliative treatment, especially in highly stressed women.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reliability of core needle biopsy for HER2-low early-stage breast cancer.
IF 2.8 3区 医学
Clinical & Translational Oncology Pub Date : 2025-03-09 DOI: 10.1007/s12094-025-03877-2
C M Ciniselli, P Verderio, V Duroni, P Baili, S Pizzamiglio, F G de Braud, S Folli, C Depretto, G Scaperrotta, M C De Santis, M G Carnevale, C De Marco, A Vingiani, G Pruneri, S Di Cosimo
{"title":"Reliability of core needle biopsy for HER2-low early-stage breast cancer.","authors":"C M Ciniselli, P Verderio, V Duroni, P Baili, S Pizzamiglio, F G de Braud, S Folli, C Depretto, G Scaperrotta, M C De Santis, M G Carnevale, C De Marco, A Vingiani, G Pruneri, S Di Cosimo","doi":"10.1007/s12094-025-03877-2","DOIUrl":"https://doi.org/10.1007/s12094-025-03877-2","url":null,"abstract":"<p><strong>Background: </strong>The reliability of core needle biopsy (CNB) for HER2-positive breast cancer is well established. However, data on HER2-low and the potential for inconsistencies with surgical samples are limited.</p><p><strong>Materials and methods: </strong>Concordance between CNB and surgical samples was assessed using the unweighted Cohen kappa statistic (Kc) in a consecutive series of 776 treatment-naïve early-stage breast cancer patients. Logistic regression models were used to evaluate the association between concordance and clinico-pathological features.</p><p><strong>Results: </strong>The agreement for HER2-positive status between CNB and surgical specimens was high at 95%, with a Kc value of 0.86 indicating almost perfect agreement. However, 65 of 123 (53%) cases initially classified as HER2-0 were reclassified as HER2 1 + or 2 + /ISH-negative, and 89 of 374 (24%) cases initially classified as HER2 1 + /2 + were HER2-0 in surgical samples. This resulted in a Kc value of 0.22, indicating fair agreement in classifying HER2-0 versus HER2-low breast cancer. Tumor size was a significant factor influencing discordance, with tumors larger than 2 cm having double the risk of misclassification.</p><p><strong>Conclusion: </strong>These findings suggest that HER2 status should be retested, particularly for large tumors initially diagnosed as HER2-0, in light of new effective therapies for HER2-low breast cancer, such as antibody-drug conjugates.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two inflammation-related genes model could predict risk in prognosis of patients with lung adenocarcinoma.
IF 2.8 3区 医学
Clinical & Translational Oncology Pub Date : 2025-03-07 DOI: 10.1007/s12094-025-03861-w
Wei Yang, Junqi Long, Gege Li, Jiashuai Xu, Yining Chen, Shijie Zhou, Zhidong Liu, Shuangtao Zhao
{"title":"Two inflammation-related genes model could predict risk in prognosis of patients with lung adenocarcinoma.","authors":"Wei Yang, Junqi Long, Gege Li, Jiashuai Xu, Yining Chen, Shijie Zhou, Zhidong Liu, Shuangtao Zhao","doi":"10.1007/s12094-025-03861-w","DOIUrl":"https://doi.org/10.1007/s12094-025-03861-w","url":null,"abstract":"<p><strong>Background: </strong>In lung adenocarcinoma (LUAD), there remains a dearth of efficacious diagnostic studies including some inflammation-related genes to identify the LUAD subgroups with different clinical outcomes.</p><p><strong>Methods: </strong>First, two molecular subgroups were identified with mRNA expression profiling from The Cancer Genome Atlas (TCGA) by K-means algorithm. Gene set enrichment analysis (GSEA), immune infiltration, and Gene set variation analysis (GSVA) were applied to explore the biological functions between these two subtypes. Then, univariate and multivariate Cox regression analyses were selected to evaluate the independence of these subtypes in LUAD. Next, lasso regression was applied to identify the high-precision mRNAs to predict the subtype with favorable prognosis. Finally, a two-mRNA model was constructed using the method of multivariate Cox regression, and the effectiveness of the model was validated in a training set (n = 310) and three independent validation sets (n = 1.</p><p><strong>Results: </strong>Comprehensive genomic analysis was conducted of 310 LUAD samples and identified two subtypes associated with molecular classification and clinical prognosis: immune-enriched and non-immune-enriched subgroup. Then, a new model was developed based on two mRNAs (MS4A1 and MS4A2) in TCGA dataset and divided these LUAD patients into high-risk and low-risk subgroup with significantly different prognosis (HR = 1.644 (95% CI 1.153-2.342); p < 0.01), which was independence of the other clinical factors (p < 0.05). In addition, this new model had similar predictive effects in another three independent validation sets (HR > 1.445, p < 0.01).</p><p><strong>Conclusions: </strong>We constructed a robust model for predicting the risk of LUAD patients and evaluated the clinical outcomes independently with strong predictive power. This model stands as a reliable guide for implementing personalized treatment strategy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HPV-driven cancer: from epidemiology to the HPV-driven tumor board proposal, everything you wanted to know but were afraid to ask.
IF 2.8 3区 医学
Clinical & Translational Oncology Pub Date : 2025-03-06 DOI: 10.1007/s12094-025-03868-3
Daniela Alterio, Michał Gola, Mattia Zaffaroni, Maria Giulia Vincini, Carlo Guglielmo Cattaneo, Cynthia Aristei, Gabriella Macchia, Vitaliana De Sanctis, Francesca DeFelice
{"title":"HPV-driven cancer: from epidemiology to the HPV-driven tumor board proposal, everything you wanted to know but were afraid to ask.","authors":"Daniela Alterio, Michał Gola, Mattia Zaffaroni, Maria Giulia Vincini, Carlo Guglielmo Cattaneo, Cynthia Aristei, Gabriella Macchia, Vitaliana De Sanctis, Francesca DeFelice","doi":"10.1007/s12094-025-03868-3","DOIUrl":"https://doi.org/10.1007/s12094-025-03868-3","url":null,"abstract":"<p><strong>Background: </strong>Human papilloma virus (HPV)-related cancers are well-known clinical entities in different body sites. Cervix, anus, and oropharynx are the most common tumors related to the virus infection. The aim of this work was to highlight similarities and differences among HPV-related cancers of different subsites.</p><p><strong>Methods: </strong>The narrative review was focused on the following topics: (1) epidemiology, (2) prognostic factors, (3) treatment approaches, (4) radiomic analysis, (5) radiosensitivity, (6) de-escalation strategies. Common aspects as well as differences have been highlighted for cervical, anal and oropharyngeal HPV-related tumors.</p><p><strong>Results: </strong>Common prognosticators in terms of patients characteristics (anemia, smoking habits), tumor histology (lymph node extracapsular extension) biological features (high circuating HPV DNA), blood cell immunomodulating response (high level of tumor-infiltrating lymphocytes and high neutrophil-to-lymphocyte ratio) as good parameters of radiosensitivity (radiosensitivity index RSI, and genomic adjusted radiation dose GARD) have been found among the analyzed tumor subsites. On the contrary, other aspects like treatment approaches (different RT techniques and doses), radiomic analysis and de-intensification strategies were found to be different among tumors.</p><p><strong>Conclusion: </strong>HPV-related tumors have several common prognostic and predictive features that do not translate into common therapeutic approaches and de-intensification strategies. A better understanding of which factors are associated with a high risk of early recurrence or favourble clinical outcomes could help in guiding clinical assessment and screening activities and might improve efforts for precision medicine.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of transarterial chemoembolization combined with radiofrequency ablation in the treatment of liver metastases from colorectal cancer.
IF 2.8 3区 医学
Clinical & Translational Oncology Pub Date : 2025-03-05 DOI: 10.1007/s12094-025-03879-0
Junwei Yin, Yongli Zhao, Junping Yin, Shanshan Yang
{"title":"Efficacy of transarterial chemoembolization combined with radiofrequency ablation in the treatment of liver metastases from colorectal cancer.","authors":"Junwei Yin, Yongli Zhao, Junping Yin, Shanshan Yang","doi":"10.1007/s12094-025-03879-0","DOIUrl":"https://doi.org/10.1007/s12094-025-03879-0","url":null,"abstract":"<p><strong>Background: </strong>Liver metastases from colorectal cancer are a common and serious complication that significantly impacts patient survival. The aim of this study is to investigate the clinical efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of liver metastases from colorectal cancer.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 120 patients with liver metastases from colorectal cancer who were treated in our hospital from January 2018 to January 2023. The patients were divided into two groups based on the treatment they received: the TACE group (n = 60) and the TACE combined with RFA group (n = 60). The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were compared between the two groups, and treatment-related adverse effects were recorded.</p><p><strong>Results: </strong>The TACE combined with RFA group showed significantly better OS (22 months vs. 18 months) and PFS (13 months vs. 10 months) compared to the TACE alone group (P < 0.05). The ORR in the TACE combined with RFA group was 61.7%, significantly higher than 40% in the TACE alone group (P < 0.05). The DCR showed no significant difference between the two groups, with 86.7% (52/60) in the TACE combined with RFA group and 78.3% (47/60) in the TACE alone group (P > 0.05). There were no significant differences in treatment-related adverse effects between the two groups (P > 0.05).</p><p><strong>Conclusion: </strong>These findings suggest that TACE combined with RFA may offer a potential option for improving OS, PFS, and ORR in patients with liver metastases from colorectal cancer, without increasing significant adverse effects, setting a new potential standard of care in the treatment of this disease.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信